This paper presents the text of the author's testimony before the Science Policy Task Force, Committee on Science and Technology, U.S. House of Representatives, on April 24, 1986. The author examines factors likely to affect future biomedical research, such as federal deficits, health-care costs and payment systems, alliances between academia and industry, and budget cuts in medical centers. Of particular importance in the future will be the need to determine the cost-effectiveness of new technologies and to reassess the system that allocates research funding. The roles of government, academia, and industry in the decisionmaking process are also reviewed.
This report is part of the RAND Corporation Paper series. The paper was a product of the RAND Corporation from 1948 to 2003 that captured speeches, memorials, and derivative research, usually prepared on authors' own time and meant to be the scholarly or scientific contribution of individual authors to their professional fields. Papers were less formal than reports and did not require rigorous peer review.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.